LUCD Projected Dividend Yield
Lucid Diagnostics Inc ( NASDAQ : LUCD )Lucid Diagnostics is a commercial-stage medical diagnostics technology company focused on patients with gastroesophageal reflux (GERD) disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). Co.'s lead products, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell Collection Device in a noninvasive office procedure, serving as a screening tool to prevent EAC deaths, through early detection of esophageal precancer and cancer in at-risk GERD patients. 20 YEAR PERFORMANCE RESULTS |
LUCD Dividend History Detail LUCD Dividend News LUCD Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |